{"id":"sirolimus-versus-mycophenolate-mofetil","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Delayed wound healing"}]},"_chembl":{"chemblId":"CHEMBL1456","moleculeType":"Small molecule","molecularWeight":"433.50"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Sirolimus inhibits the mammalian target of rapamycin (mTOR), blocking T-cell and B-cell proliferation by preventing progression through the cell cycle. Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing lymphocyte proliferation. Both are used as immunosuppressive agents in transplant recipients, but differ in mechanism and side effect profiles.","oneSentence":"This is a comparative study of two immunosuppressive agents: sirolimus (mTOR inhibitor) and mycophenolate mofetil (IMPDH inhibitor), used to prevent organ rejection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:47.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients"},{"name":"Renal transplantation"}]},"trialDetails":[{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT05327023","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-23","conditions":"Hematologic Neoplasms","enrollment":430},{"nctId":"NCT04959175","phase":"PHASE1, PHASE2","title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-23","conditions":"Hematologic Neoplasms","enrollment":320},{"nctId":"NCT06799195","phase":"PHASE2","title":"Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-06-23","conditions":"Hematological Malignancies, Graft-versus-Host Disease (GVHD)","enrollment":126},{"nctId":"NCT06973668","phase":"PHASE2","title":"A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-22","conditions":"AML","enrollment":80},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT00544115","phase":"PHASE2","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2001-10-16","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":260},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03192397","phase":"PHASE1, PHASE2","title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2017-08-09","conditions":"Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission","enrollment":35},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT06279494","phase":"PHASE1, PHASE2","title":"Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-03","conditions":"Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia","enrollment":6},{"nctId":"NCT00681213","phase":"PHASE4","title":"Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-05","conditions":"Adult Primary Kidney Transplantation","enrollment":150},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT00352976","phase":"PHASE2, PHASE3","title":"TBI Dose De-escalation for Fanconi Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-05-18","conditions":"Fanconi Anemia","enrollment":83},{"nctId":"NCT00140543","phase":"PHASE3","title":"European Trial of Immunosuppression in SPK Tx","status":"COMPLETED","sponsor":"EUROSPK Study Group","startDate":"2002-02","conditions":"Diabetes Mellitus, Type 1, Diabetic Nephropathy","enrollment":228},{"nctId":"NCT04849533","phase":"PHASE4","title":"Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2021-04-09","conditions":"Kidney Transplant Rejection","enrollment":120},{"nctId":"NCT02334488","phase":"PHASE3","title":"Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-12-11","conditions":"Chronic Kidney Disease","enrollment":329},{"nctId":"NCT02423915","phase":"PHASE1","title":"Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-30","conditions":"Leukemia, Lymphoma","enrollment":5},{"nctId":"NCT00506948","phase":"PHASE2","title":"Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09","conditions":"Hematological Malignancies, Myelodysplastic Syndrome, Leukemia","enrollment":13},{"nctId":"NCT04471441","phase":"PHASE4","title":"Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-06-30","conditions":"Liver Transplant","enrollment":150},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT01251575","phase":"PHASE2","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-12-01","conditions":"Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma","enrollment":77},{"nctId":"NCT00105001","phase":"PHASE2","title":"Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2004-11","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia","enrollment":210},{"nctId":"NCT01231412","phase":"PHASE3","title":"Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-11","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma","enrollment":174},{"nctId":"NCT01379209","phase":"PHASE1, PHASE2","title":"Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)","status":"COMPLETED","sponsor":"Regimmune Corporation","startDate":"2011-09","conditions":"Graft Versus Host Disease","enrollment":68},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT01634217","phase":"PHASE1","title":"Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-11-08","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":16},{"nctId":"NCT01595984","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-03","conditions":"Kidney Failure","enrollment":90},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT01707849","phase":"PHASE3","title":"The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation","status":"COMPLETED","sponsor":"Hospital Vall d'Hebron","startDate":"2012-10","conditions":"Hepatitis C Recurrence After Liver Transplant","enrollment":18},{"nctId":"NCT00533442","phase":"PHASE2","title":"Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-09","conditions":"Type 1 Diabetes","enrollment":170},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00425308","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":30},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT01680861","phase":"PHASE3","title":"Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium","status":"COMPLETED","sponsor":"Gaetano Ciancio","startDate":"2012-11","conditions":"Transplant; Failure, Kidney","enrollment":32},{"nctId":"NCT00170859","phase":"PHASE4","title":"Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08","conditions":"Heart Transplantation","enrollment":""},{"nctId":"NCT01680952","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-09","conditions":"Kidney Transplant Patients","enrollment":158},{"nctId":"NCT00693446","phase":"PHASE4","title":"A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids","status":"UNKNOWN","sponsor":"Nantes University Hospital","startDate":"2004-04","conditions":"Pancreas Transplantation, Kidney Transplantation","enrollment":118},{"nctId":"NCT01244906","phase":"PHASE2","title":"Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2010-12","conditions":"Hematologic Neoplasms","enrollment":26},{"nctId":"NCT01134952","phase":"PHASE4","title":"Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"London Health Sciences Centre","startDate":"2010-06","conditions":"Hepatitis C","enrollment":11},{"nctId":"NCT00548717","phase":"PHASE2","title":"Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-10","conditions":"Graft-vs-Host Disease","enrollment":15},{"nctId":"NCT00296361","phase":"PHASE3","title":"To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-10","conditions":"Kidney Transplantation","enrollment":634},{"nctId":"NCT00332839","phase":"PHASE4","title":"Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Renal Transplantation","enrollment":93},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT02117596","phase":"NA","title":"Calcineurin Inhibitor Based Immunosuppression Withdrawal","status":"COMPLETED","sponsor":"Pediatric Nephrology of Alabama","startDate":"2007-11","conditions":"Renal Transplant","enrollment":52},{"nctId":"NCT01079143","phase":"PHASE3","title":"Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Renal Interstitial Fibrosis","enrollment":194},{"nctId":"NCT00658320","phase":"PHASE3","title":"Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Kidney Transplantation","enrollment":122},{"nctId":"NCT00555373","phase":"NA","title":"Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression","status":"COMPLETED","sponsor":"Pediatric Nephrology of Alabama","startDate":"2007-11","conditions":"Renal Transplant","enrollment":52},{"nctId":"NCT00137345","phase":"PHASE3","title":"Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-06","conditions":"Kidney Transplant","enrollment":500},{"nctId":"NCT00300274","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-01","conditions":"Graft Rejection","enrollment":721},{"nctId":"NCT00254709","phase":"PHASE4","title":"Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-10","conditions":"Kidney Failure, Graft Rejection, Aged","enrollment":66},{"nctId":"NCT00267189","phase":"PHASE3","title":"RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Liver Transplantation","enrollment":145},{"nctId":"NCT00966836","phase":"PHASE3","title":"Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2009-04","conditions":"Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection","enrollment":100},{"nctId":"NCT00903188","phase":"PHASE4","title":"Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2008-10","conditions":"Renal Transplantation","enrollment":152},{"nctId":"NCT00309270","phase":"PHASE2","title":"Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2003-02","conditions":"Kidney Transplant","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":252,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"sirolimus versus mycophenolate mofetil","genericName":"sirolimus versus mycophenolate mofetil","companyName":"EUROSPK Study Group","companyId":"eurospk-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a comparative study of two immunosuppressive agents: sirolimus (mTOR inhibitor) and mycophenolate mofetil (IMPDH inhibitor), used to prevent organ rejection. Used for Prevention of organ rejection in transplant recipients, Renal transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}